Treatment of head and neck cancer in the elderly

References

• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83(4):489–501.
   PubMed Web of Science ®Google Scholar
• Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–1154.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005;92(8):1341–1348.
   PubMed Web of Science ®Google Scholar
• Narayan TV, Revanna GM, Hallikeri U, et al. dental caries and periodontal disease status in patients with oral squamous cell carcinoma: a screening study in urban and semiurban population of Karnataka. J Maxillofac Oral Surg. 2014;13(4):435–443.
   PubMedGoogle Scholar
• Tremblay S, Pintor Dos Reis P, Bradley G, et al. Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Arch Otolaryngol Head Neck Surg. 2006;132(9):958–966.
   PubMedGoogle Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–3584.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–1160.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Lui VW, Egloff AM, et al. Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma. JAMA Oncol. 2015;1(2):238–244.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.
   PubMed Web of Science ®Google Scholar
• Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429–1435.
   PubMed Web of Science ®Google Scholar
• D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–1956.
   PubMed Web of Science ®Google Scholar
• Johansen J, Grau Eriksen J. Academy of Geriatric Cancer R. Trends in cancer of the head and neck in the elderly in Denmark, 1980–2012. Acta Oncol. 2016;55(Suppl 1):13–18.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–269.
   PubMedGoogle Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
   PubMed Web of Science ®Google Scholar
• Sano D, Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016 Jun 23. [Epub ahead of print].
   Google Scholar
• Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412–423.
   PubMedGoogle Scholar
• Mirghani H, Amen F, Tao Y, et al. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015;41(10):844–852.
   PubMed Web of Science ®Google Scholar
• Egawa N, Egawa K, Griffin H, et al. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863–3890.
   PubMed Web of Science ®Google Scholar
• Markey J, Knott PD, Fritz MA, et al. Recent advances in head and neck free tissue transfer. Curr Opin Otolaryngol Head Neck Surg. 2015;23(4):297–301.
   PubMed Web of Science ®Google Scholar
• Byrd JK, Ferris RL. Is there a role for robotic surgery in the treatment of head and neck cancer? Curr Treat Options Oncol. 2016;17(6):29.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Civantos FJ, Brumund KT, et al. [(99m)Tc]Tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck: results of a phase III multi-institutional trial. Ann Surg Oncol. 2015;22(11):3708–3715.
   PubMed Web of Science ®Google Scholar
• Porceddu SV, Campbell B, Rischin D, et al. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;60(2):365–373.
   PubMed Web of Science ®Google Scholar
• Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? The Laryngoscope. 2000;110(3Pt 2 Suppl 93):1–18.
   PubMed Web of Science ®Google Scholar
• Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115(24):5723–5733.
   PubMed Web of Science ®Google Scholar
• Sanguineti G, Forastiere AA. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. Nat Clin Pract Oncol. 2008;5(12):694–695.
   PubMedGoogle Scholar
• Grégoire V, Langendijk JA, Nuyts S. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol. 2015;33(29):3277–3284.
   PubMed Web of Science ®Google Scholar
• Kao J, Lavaf A, Teng MS, et al. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008;71(2):362–370.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
   PubMed Web of Science ®Google Scholar
• Strojan P, Vermorken JB, Beitler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck. 2016;38(Suppl 1):E2151–2158.
   Google Scholar
• Ang KK, Chen A, Curran WJ Jr, et al. Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). Cancer. 2012;118(23):5783–5792.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145–153.
   PubMed Web of Science ®Google Scholar
• Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clinl Oncol: off J Am Soc Clin Oncol. 2004;22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clinl Oncol: off J Am Soc Clin Oncol. 2005;23(34):8636–8645.
   PubMed Web of Science ®Google Scholar
• Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506.
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–1715.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–3567.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257–263.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007;25(3):182–188.
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann oncol: off J Eur Soc Med Oncol /ESMO. 2015;26(9):1941–1947.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(5):583–594.
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864–1871.
   PubMed Web of Science ®Google Scholar
• Mevio N, Bertino G, Occhini A, et al. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori. 2012;98(3):308–313.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.
   PubMed Web of Science ®Google Scholar
• Rubinstein PG, Lindgren V, Setty S, et al. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2011;29(9):e222–225.
   Google Scholar
• Peddi P, Paryani B, Takalkar A, et al. Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight. Onco Targets Ther. 2016;9:705–709.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177.
   PubMed Web of Science ®Google Scholar
• Madoz-Gurpide J, Zazo S, Chamizo C, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med. 2015;13:282.
   PubMed Web of Science ®Google Scholar
• Bossi P, Alfieri S. Investigational drugs for head and neck cancer. Expert Opin Investig Drugs. 2016;25(7)797–810.
   PubMed Web of Science ®Google Scholar
• Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726.
   PubMed Web of Science ®Google Scholar
• Amini A, Jones BL, McDermott JD, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016;122(10):1533–1543.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Chung J, Shin HJ, et al. Induction chemotherapy of docetaxel and Cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. Cancer Res Treat. 2007;39(1):1–5.
   PubMedGoogle Scholar
• Feinstein AR, Schimpff CR, Andrews JF Jr, et al. Cancer of the larynx: a new staging system and a re-appraisal of prognosis and treatment. J Chronic Dis. 1977;30(5):277–305.
   PubMedGoogle Scholar
• Piccirillo JF, Wells CK, Sasaki CT, et al. New clinical severity staging system for cancer of the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol. 1994;103(2):83–92.
   PubMed Web of Science ®Google Scholar
• Paleri V, Wight RG. Applicability of the adult comorbidity evaluation – 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol. 2002;116(3):200–205.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–2447.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267.
   PubMed Web of Science ®Google Scholar
• Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997;107(11 Pt 1):1469–1475.
   PubMed Web of Science ®Google Scholar
• Datema FR, Ferrier MB, van der Schroeff MP, et al. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010;32(6):728–736.
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27(7–8):387–404.
   PubMedGoogle Scholar
• Hall SF, Rochon PA, Streiner DL, et al. Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002;112(11):1988–1996.
   PubMed Web of Science ®Google Scholar
• Ribeiro KC, Kowalski LP, Latorre MR. Impact of comorbidity, symptoms, and patients’ characteristics on the prognosis of oral carcinomas. Arch Otolaryngol Head Neck Surg. 2000;126(9):1079–1085.
   PubMedGoogle Scholar
• Borggreven PA, Kuik DJ, Langendijk JA, et al. Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction. Oral Oncol. 2005;41(4):358–364.
   PubMed Web of Science ®Google Scholar
• Castro MA, Dedivitis RA, Ribeiro KC. Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2007;69(3):146–152.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Shahrokni A. Moving beyond karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016;2016:6186543.
   PubMed Web of Science ®Google Scholar
• Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187–193.
   PubMed Web of Science ®Google Scholar
• Sadat F, Wienke A, Dunst J, et al. Survival of patients with head and neck cancer. Impact of physical status and comorbidities. Strahlenther Onkol. 2012;188(1):62–70.
   PubMed Web of Science ®Google Scholar
• Taylor AE, Olver IN, Sivanthan T, et al. Observer error in grading performance status in cancer patients. Support Care Cancer. 1999;7(5):332–335.
   PubMed Web of Science ®Google Scholar
• Correa GT, Bandeira GA, Cavalcanti BG, et al. Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012;20(11):2679–2685.
   PubMed Web of Science ®Google Scholar
• Wang JR, Habbous S, Espin-Garcia O, et al. Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(5):736–742.
   PubMed Web of Science ®Google Scholar
• Bøje CR, Dalton SO, Grønborg TK, et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol. 2013;52(2):285–293.
   PubMed Web of Science ®Google Scholar
• Sanabria A, Carvalho AL, Vartanian JG, et al. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol. 2007;14(4):1449–1457.
   PubMed Web of Science ®Google Scholar
• Liu CT, Chiu TJ, Huang TL, et al. Impact of comorbidity on survival for locally advanced head and neck cancer patients treated by radiotherapy or radiotherapy plus chemotherapy. Chang Gung Med J. 2010;33(3):283–291.
   PubMedGoogle Scholar
• Alho OP, Hannula K, Luokkala A, et al. Differential prognostic impact of comorbidity in head and neck cancer. Head Neck. 2007;29(10):913–918.
   PubMed Web of Science ®Google Scholar
• Derks W, de Leeuw JR, Hordijk GJ, et al. Reasons for non-standard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol. 2005;262(1):21–26.
   PubMed Web of Science ®Google Scholar
• Sanabria A, Carvalho AL, Vartanian JG, et al. Factors that influence treatment decision in older patients with resectable head and neck cancer. Laryngoscope. 2007;117(5):835–840.
   PubMed Web of Science ®Google Scholar
• Yang R, Lubek JE, Dyalram D, et al. Head and neck cancer surgery in an elderly patient population: a retrospective review. Int J Oral Maxillofac Surg. 2014;43(12):1413–1417.
   PubMed Web of Science ®Google Scholar
• Shuman AG, Korc-Grodzicki B, Shklar V, et al. A new care paradigm in geriatric head and neck surgical oncology. J Surg Oncol. 2013;108(3):187–191.
   PubMed Web of Science ®Google Scholar
• Clayman GL, Eicher SA, Sicard MW, et al. Surgical outcomes in head and neck cancer patients 80 years of age and older. Head Neck. 1998;20(3):216–223.
   PubMed Web of Science ®Google Scholar
• Peters TT, Post SF, van Dijk BA, et al. Free flap reconstruction for head and neck cancer can be safely performed in both young and elderly patients after careful patient selection. Eur Arch Otorhinolaryngol. 2015;272(10):2999–3005.
   PubMed Web of Science ®Google Scholar
• Nao EE, Dassonville O, Chamorey E, et al. Head and neck free-flap reconstruction in the elderly. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128(2):47–51.
   PubMed Web of Science ®Google Scholar
• Chen JH, Yen YC, Yang HC, et al. Curative-intent aggressive treatment improves survival in elderly patients with locally advanced head and neck squamous cell carcinoma and high comorbidity index. Medicine (Baltimore). 2016;95(14):e3268.
   Google Scholar
• Yoo SH, Roh JL, Choi SH, et al. Incidence and risk factors for morbidity and mortality in elderly head and neck cancer patients undergoing major oncological surgery. J Cancer Res Clin Oncol. 2016;142(6):1343–1351.
   PubMed Web of Science ®Google Scholar
• Geinitz H, Zimmermann FB, Molls M. Radiotherapy of the elderly patient. Radiotherapy tolerance and results in older patients. Strahlenther Onkol. 1999;175(3):119–127.
   PubMed Web of Science ®Google Scholar
• Khor RC, Bressel M, Tedesco J, et al. Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years. Med J Aust. 2015;202(3):153–155.
   PubMed Web of Science ®Google Scholar
• Pignon T, Jc H, van den Bogaert W, et al. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer. 1996;32A(12):2075–2081.
   PubMed Web of Science ®Google Scholar
• Bøje CR, Dalton SO, Primdahl H, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014;110(1):91–97.
   PubMed Web of Science ®Google Scholar
• Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6(5):399–412.
   PubMed Web of Science ®Google Scholar
• Kimmick GG, Fleming R, Muss HB, et al. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging. 1997;10(1):34–49.
   PubMed Web of Science ®Google Scholar
• Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am. 2000;14(1):193–212, x–xi.
   Web of Science ®Google Scholar
• Bahig H, Fortin B, Alizadeh M, et al. Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015;51(5):521–528.
   PubMed Web of Science ®Google Scholar
• Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol. 2004;22(2):262–268.
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Vock J, Chi A, et al. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol. 2012;188(8):677–683.
   PubMed Web of Science ®Google Scholar
• Airoldi M, Cortesina G, Giordano C, et al. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130(2):161–166.
   PubMedGoogle Scholar
• Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–1205.
   PubMed Web of Science ®Google Scholar
• Xu B, Boero IJ, Hwang L, et al. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015;121(8):1303–1311.
   PubMed Web of Science ®Google Scholar
• Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20(1):1–7.
   PubMed Web of Science ®Google Scholar
• Paleri V, Wight RG, Davies GR. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck. 2003;25(12):1019–1026.
   PubMed Web of Science ®Google Scholar
• de Cassia Braga Ribeiro K, Kowalski LP, Latorre Mdo R. Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2003;129(2):219–228.
   PubMedGoogle Scholar
• Hathaway B, Johnson JT, Piccirillo JF, et al. Chemoradiation for metastatic SCCA: role of comorbidity. Laryngoscope. 2001;111(11 Pt 1):1893–1895.
   PubMed Web of Science ®Google Scholar
• Rathod S, Livergant J, Klein J, et al. A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment. Oral Oncol. 2015;51(10):888–900.
   PubMed Web of Science ®Google Scholar
• van der Schroeff MP, Derks W, Hordijk GJ, et al. The effect of age on survival and quality of life in elderly head and neck cancer patients: a long-term prospective study. Eur Arch Otorhinolaryngol. 2007;264(4):415–422.
   PubMed Web of Science ®Google Scholar
• Pottel L, Lycke M, Boterberg T, et al. G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. BMC Cancer. 2015;15:875.
   PubMed Web of Science ®Google Scholar
• Genther DJ, Gourin CG. Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery in the elderly. Head Neck. 2015;37(5):685–693.
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98.
   PubMed Web of Science ®Google Scholar
• Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: current status. GMS Curr Top Otorhinolaryngol Head Neck Surg. Laryngorhinootologie. 2012;91(Suppl 1):S123–S143.
   Google Scholar
• Schweitzer VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 1993;103(4 Pt 2):1–52.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, D’Cruz A, Vermorken JB, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review. Oral Oncol. 2016;53:10–16.
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18(7):1458–1464.
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Adelstein DJ, Rybicki LA, et al. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Head Neck. 2015;37(11):1583–1589.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40.
   PubMed Web of Science ®Google Scholar
• Linot B, Augereau P, Breheret R, et al. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer. 2014;22(10):2831–2837.
   PubMed Web of Science ®Google Scholar
• Wen J, Zeng M, Shu Y, et al. Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordr). 2015;37(6):112.
   PubMed Web of Science ®Google Scholar
• Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol. 2003;89(1):112–115.
   PubMed Web of Science ®Google Scholar
• Tsan DL, Lin CY, Kang CJ, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7:215.
   PubMed Web of Science ®Google Scholar
• Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22(23):4665–4673.
   PubMed Web of Science ®Google Scholar
• Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol. 2004;22(23):4657–4659.
   PubMed Web of Science ®Google Scholar
• Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11(7):1173–1179.
   PubMed Web of Science ®Google Scholar
• Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–186.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28.
   PubMed Web of Science ®Google Scholar
• Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncol. 2010;46(6):439–441.
   PubMed Web of Science ®Google Scholar
• Ghosh-Laskar S, Yathiraj PH, Dutta D, et al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: long-term results. Head Neck. 2016;38(Suppl 1):E1481–1487.
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–2950.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;93(2):127–135.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Rodeck U. Skinflammation and drug toxicity–a delicate balance. Sci Transl Med. 2013;5(199):199fs33.
   PubMed Web of Science ®Google Scholar
• Fülöp T, Dupuis G, Witkowski JM, et al. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68(2):84–91.
   PubMedGoogle Scholar
• Jehn CF, Böning L, Kröning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012;106(2):274–278.
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373–382.
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646–1654.
   PubMed Web of Science ®Google Scholar
• Rodríguez MO, Rivero TC, Del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9(5):343–349.
   PubMed Web of Science ®Google Scholar
• Xu S, Ramos Suzarte M, Bai X, et al. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget. 2016 Mar 31. doi:10.18632/oncotarget.8516. [Epub ahead of print].
   Web of Science ®Google Scholar
• Nwizu T, Adelstein D. Pharmacotherapy of head and neck cancer. Expert Opin Pharmacother. 2015;16(16):2409–2422.
   PubMed Web of Science ®Google Scholar
• Hamoir M, Schmitz S, Gregoire V. The role of neck dissection in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 2014;15(4):611–624.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944.
   PubMed Web of Science ®Google Scholar
• Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952.
   PubMed Web of Science ®Google Scholar
• Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843–850.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–2098.
   PubMed Web of Science ®Google Scholar
• Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–264.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–2743.
   PubMed Web of Science ®Google Scholar
• Wong LY, Wei WI, Lam LK, et al. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25(11):953–959.
   PubMed Web of Science ®Google Scholar
• Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26(34):5518–5523.
   PubMed Web of Science ®Google Scholar
• Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283–289.
   PubMed Web of Science ®Google Scholar
• The Liverpool Head and Neck Oncology Group. A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer. 1990;61(2):311–315.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245–1251.
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–526.
   PubMed Web of Science ®Google Scholar
• Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23(2):128–131.
   PubMed Web of Science ®Google Scholar
• Baghi M, Hambek M, Wagenblast J, et al. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006;26(1B):585–590.
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–8654.
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38(1):17–23.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, van den Brakel JH, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011;187(6):3383–3390.
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Lammerts Van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173(7):4699–4707.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333–343.
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31(11):1405–1414.
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–350.
   PubMed Web of Science ®Google Scholar
• Clement PM, Gauler T, Machiels JH, et al. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016;27(8):1585–1593.
   PubMed Web of Science ®Google Scholar
• Sunaoshi M, Amasaki Y, Hirano-Sakairi S, et al. The effect of age at exposure on the inactivating mechanisms and relative contributions of key tumor suppressor genes in radiation-induced mouse T-cell lymphomas. Mutat Res. 2015;779:58–67.
   PubMed Web of Science ®Google Scholar
• Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–769.
   PubMed Web of Science ®Google Scholar
• Wang Z, Martin D, Molinolo AA, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst. 2014;106:9.
   Google Scholar
• Lattanzio L, Tonissi F, Monteverde M, et al. Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Invest New Drugs. 2015;33(2):310–320.
   PubMed Web of Science ®Google Scholar
• D’Amato V, Rosa R, D’Amato C, et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer. 2014;110(12):2887–2895.
   PubMed Web of Science ®Google Scholar
• Keam B, Kim S, Ahn YO, et al. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015;35(1):175–182.
   PubMed Web of Science ®Google Scholar
• Qian G, Jiang N, Wang D, et al. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer. 2015;121(20):3600–3611.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27(28):3944–3956.
   PubMed Web of Science ®Google Scholar
• Jiang N, Wang D, Hu Z, et al. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther. 2014;13(7):1826–1836.
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Starr MM, et al. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014;13:242.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
   PubMed Web of Science ®Google Scholar
• Leibowitz MS, Andrade Filho PA, Ferrone S, et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother. 2011;60(4):525–535.
   PubMed Web of Science ®Google Scholar
• Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33(29):3293–3304.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Jie HB, Schuler PJ, Lee SC, et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200–2210.
   PubMed Web of Science ®Google Scholar
• Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18(6):573–583.
   PubMedGoogle Scholar
• Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37.
   PubMed Web of Science ®Google Scholar
• Shestak KC, Jones NF, Wu W, et al. Effect of advanced age and medical disease on the outcome of microvascular reconstruction for head and neck defects. Head Neck. 1992;14(1):14–18.
   PubMed Web of Science ®Google Scholar
• Kowalski LP, Alcantara PS, Magrin J, et al. A case-control study on complications and survival in elderly patients undergoing major head and neck surgery. Am J Surg. 1994;168(5):485–490.
   PubMed Web of Science ®Google Scholar
• Allal AS, Maire D, Becker M, et al. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer. 2000;88(3):648–652.
   PubMed Web of Science ®Google Scholar
• Huang SH, O’Sullivan B, Waldron J, et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys. 2011;79(1):46–51.
   PubMed Web of Science ®Google Scholar
• Michal SA, Adelstein DJ, Rybicki LA, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck. 2012;34(8):1147–1152.
   PubMed Web of Science ®Google Scholar
• Merlano MC, Monteverde M, Colantonio I, et al. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol. 2012;48(10):1051–1057.
   PubMed Web of Science ®Google Scholar